Category - Markets

Maxim Group raised its price target for Quantum Genomics SA (Euronext Growth – FR0011648971 – ALQGC) to €9 from €6 after the company held a recent key opinion leader and investor day. The stock closed at €5...

Analysts at Canaccord Genuity and BTIG launched coverage of Vapotherm (NYSE:VAPO) with “buy” ratings and price targets of $25 and $26, respectively. The stock closed at $20.93 on Dec. 7. Vapotherm sells Precision Flow...

Stifel downgraded Conatus Pharmaceuticals (NASDAQ:CNAT) to “hold” from “buy” and slashed its price target to $4 from $10 after the company’s ENCORE-PH trial missed its pre-specified primary endpoint. The stock closed at...

Echelon Wealth Partners upgraded ProMetic Life Sciences (TSX:PLI) to “speculative buy” from “hold” but reduced its price target to 60 cents from $1 after the company announced plans for Phase 3 testing of its anti...

Roth Capital Partners initiated coverage of BioSig Technologies (NASDAQ:BSGM) with a “buy” rating and $14 price target. The stock closed at $3.97 on Dec. 4. BioSig is a medical device company developing the PURE EP...

Roth Capital Partners launched coverage of CorMedix (NASDAQ:CRMD) with a “buy” rating and price target of $6. The stock closed at $1.35 on Dec. 4. CorMedix is developing Neutrolin for the prevention of catheter-related...

BTIG initiated coverage of Valeritas Holdings (NASDAQ:VLRX) with a “buy” rating and price target of $1. The stock closed at 39 cents on Dec. 3. Valeritas sells V-Go, the only pump on the market for Type 2 diabetes...

Maxim Group initiated coverage of Agile Therapeutics (NASDAQ:AGRX) with a “buy” rating and $3 price target. The stock closed at 81 cents on Nov. 28.

JP Morgan launched coverage of Orchard Therapeutics (NASDAQ:ORTX) with an “overweight” rating and December 2019 price target of $25. The stock closed at $16.75 on Nov. 22. Analyst Anupam Rama writes that Orchard, in a...

JP Morgan initiated coverage on Audentes Therapeutics (NASDAQ:BOLD) with an “overweight” rating and December 2019 price target of $35. The stock closed at $23.91 on Nov. 22. “Audentes shares have pulled back 40%-plus...